Key result
Andexanet alfa and ciraparantag rapidly reverse Factor Xa inhibitor anticoagulation in early-phase volunteer studies and preclinical bleeding models.
Why the study?
Do andexanet alfa and ciraparantag safely and effectively reverse the anticoagulant effects of Factor Xa inhibitors and other anticoagulants?
Do andexanet alfa and ciraparantag safely and effectively reverse the anticoagulant effects of Factor Xa inhibitors and other anticoagulants?
Andexanet alfa and ciraparantag demonstrate rapid, well-tolerated reversal of Factor Xa inhibitors in preclinical and healthy volunteer studies, offering promising targeted antidotes for patients experiencing life-threatening anticoagulation-related bleeding.
Answers are grounded in this paper and cite their sources.
Supports reversal agent development; leaves open clinical safety and efficacy in bleeding patients.
Oral Factor Xa (FXa) inhibitors, a growing class of direct-acting anticoagulants, are frequently used to prevent stroke and systemic embolism in patients with atrial fibrillation and to prevent and treat venous thromboembolism. These drugs reduce the risk of clotting at the expense of increasing the risk of bleeding, and currently they have no specific reversal agent. However, andexanet alfa, a recombinant modified FXa decoy molecule, is in a late-phase clinical trial in bleeding patients, and ciraparantag, a small molecule that appears to reverse many anticoagulants including the FXa inhibitors, is in development. This review summarizes the published data to date on both drugs, which have the potential to change the management approach to patients with FXa inhibitor-associated major hemorrhage.
No takes yet. Share an insight, caveat, or question.
Milling et al. (2016) conducted a review in Factor Xa inhibitor-associated anticoagulation and major hemorrhage. Andexanet alfa and ciraparantag was evaluated on Reversal of anticoagulation (anti-FXa activity and whole blood clotting time) and clinical hemostatic efficacy. Andexanet alfa and ciraparantag rapidly reverse Factor Xa inhibitor anticoagulation in early-phase volunteer studies and preclinical bleeding models.
Synapse has enriched 10 related papers. Consider them for comparative context: